Ursodeoxycholic acid for nonalcoholic steatohepatitis

European Journal of Gastroenterology and Hepatology

Volumn 24, Issue 11, 2012, Pages 1247-1253

  Wu, Sheng Di ^a   Li, Lei ^a   Wang, Ji Yao ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Aminotransferases; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Randomized clinical trials; Ursodeoxycholic acid

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; PLACEBO; URSODEOXYCHOLIC ACID;

BILIRUBIN BLOOD LEVEL; CHEMICAL ANALYSIS; COCHRANE LIBRARY; CONTROLLED STUDY; DATA BASE; DRUG EFFECT; DRUG MEGADOSE; EMBASE; ENZYME ACTIVITY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MEDLINE; META ANALYSIS; MONOTHERAPY; NONALCOHOLIC FATTY LIVER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STANDARD; STATISTICAL SIGNIFICANCE;

ADULT; ANIMALS; BIOLOGICAL MARKERS; BIOPSY; CHI-SQUARE DISTRIBUTION; CHOLAGOGUES AND CHOLERETICS; FATTY LIVER; HUMANS; LIVER; ODDS RATIO; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID;

EID: 84867334189     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3283572ec0     Document Type: Review

References (61)

1. Caldwell SH, Crespo DM. The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J Hepatol 2004; 40:578-584. (Pubitemid 38367778)
2. Ratziu V, Poynard T. Assessing the outcome of nonalcoholic steatohepatitis? It's time to get serious. Hepatology 2006; 44:802-805. (Pubitemid 46489542)
3. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohortstudy. Gastroenterology 2005; 129:113-121. (Pubitemid 41002048)
4. Ekstedt M, Franzen LE, Mathiesen UL,Thorelius L, Holmqvist M, BodemarG, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44:865-873. (Pubitemid 46489550)
5. Jepsen P,Vilstrup H, Mellemkjaer L,Thulstrup AM, Olsen JH, Baron JA, etal. Prognosis of patients with a diagnosis of fatty liver - a registry-based cohortstudy. Hepatogastroenterology2003; 50:2101-2104. (Pubitemid 37468003)
6. Soderberg C, Stal P, Askling J, Glaumann H, Lindberg G, Marmur J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010; 51:595-602.
7. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, etal. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120:1183-1192. (Pubitemid 32246672)
8. Crespo J, Cayon A, Fernandez-Gil P, Hernandez-Guerra M, Mayorga M, Dominguez-Diez A, et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 2001; 34:1158-1163. (Pubitemid 33096588)
9. Pagano C, Soardo G, Esposito W, Fallo F, Basan L, Donnini D, etal. Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur J Endocrinol 2005; 152:113-11 8.
10. Zamara E, Novo E, Marra F, Gentilini A, Romanelli RG, Caligiuri A, et al. 4-Hydroxynonenal as a selective pro-fibrogenic stimulus for activated human hepatic stellate cells. J Hepatol 2004; 40:60-68. (Pubitemid 38067269)
11. Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'. J Hepatol 2001; 35: 134-146. (Pubitemid 32646237)
12. Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, Lindor KD, et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology2003; 125:437-443. (Pubitemid 36929425)
13. Amaral JD,Viana RJ, Ramalho RM, Steer CJ, Rodrigues CM. Bile acids: regulation of apoptosis by ursodeoxycholic acid. J Lipid Res 2009; 50:1721-1734.
14. Kugelmas M, Hill DB,Vivian B, Marsano L, McClain CJ. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003; 38:413-419. (Pubitemid 36919862)
15. Neuman M, Angulo P, Malkiewicz I, Jorgensen R, Shear N, Dickson ER, et al. Tumor necrosis factor-alpha and transforming growth factor-beta reflect severity of liver damage in primary biliary cirrhosis. J Gastroenterol Hepatol 2002; 17:196-202. (Pubitemid 34415674)
16. Ozcan U, Yilmaz E, Ozcan L, Furuhashi M, Vaillancourt E, Smith RO, et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 2006; 313:1137-1140. (Pubitemid 44300242)
17. Kars M, Yang L, Gregor MF, Mohammed BS, Pietka TA, Finck BN, et al. Tauroursodeoxycholic acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women. Diabetes 2010; 59:1899-1905.
18. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6:e1000097.
19. Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions, version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011.
20. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21:1539-1558. (Pubitemid 34746062)
21. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327:557-560. (Pubitemid 37088507)
22. Lindor KD, Kowdley KV, Heathcote EJ, Harrison ME, Jorgensen R, Angulo P, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004; 39:770-778. (Pubitemid 38337657)
23. Dufour JF, Oneta CM, Gonvers JJ, Bihl F, Cerny A, Cereda JM, et al. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2006; 4: 1537-1543. (Pubitemid 44880031)
24. Leuschner UF, Lindenthal B, Herrmann G, Arnold JC, Rossle M, Cordes HJ, et al. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology2010; 52:472-479.
25. Ratziu V, de Ledinghen V, Oberti F, Mathurin P,Wartelle-Bladou C, Renou C, et al. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol 2011; 54:1011-1019.
26. Adams LA, Angulo P, Petz J, Keach J, Lindor KD. A pilot trial of high-dose ursodeoxycholic acid in nonalcoholic steatohepatitis. Hepatol Int 2010; 4:628-633.
27. Santos VN, Lanzoni VP, Szejnfeld J, Shigueoka D, Parise ER. A randomized double-blind study of the short-time treatment of obese patients with nonalcoholic fatty liver disease with ursodeoxycholic acid. Braz J Med Biol Res 2003; 36:723-729. (Pubitemid 36874723)
28. Ersoz G, Gunsar F, Karasu Z, Akay S, Batur Y, Akarca US. Management of fatty liver disease with vitamin E and C compared to ursodeoxycholic acid treatment. Turk J Gastroenterol 2005; 16:124-128. (Pubitemid 44869965)
29. Tuncer I. The comparative effects of pentoxifylline and ursodeoxycholic acid on IL-1(beta), IL-6, IL-8 AND TNF-(alpha) levels in nonalcoholic fatty liver. East J Med 2003; 8:2732.
30. Zhang SJ, Chen ZX, Jiang KP, Cheng YH, Gu YL. The effect of QuYuHuaTanTongLuo Decoction on the non-alcoholic steatohepatitis. Complement Ther Med 2008; 16:192-198.
31. Georgescu EF, Georgescu M. Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study. J Gastrointestin Liver Dis 2007; 16:39-46. (Pubitemid 46548588)
32. Kiyici M, Gulten M, Gurel S, Nak SG, Dolar E, Savci G, et al. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can J Gastroenterol 2003; 17:713-718. (Pubitemid 38072335)
33. Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 1996; 23:1464-1467.
34. Alavian SM. Vitamin E + ursodeoxycholic acid (UDCA) versus vitamin E for the treatment of non-alcoholic steatohepatitis (NASH). J Isfahan Med Sch 2010; 28:534-541.
35. Madan K, Batra Y, Gupta DS, Chander B, Anand RKD, Singh R, et al. Vitamin E-based therapy is effective in ameliorating transaminasemia in nonalcoholic fatty liver disease. Indian J Gastroenterol 2005; 24:251-255. (Pubitemid 44326097)
36. Mendez-Sanchez N, Gonzalez V, Chavez-Tapia N, Ramos MH, Uribe M. Weight reduction and ursodeoxycholic acid in subjects with nonalcoholic fatty liver disease. A double-blind, placebo-controlled trial. Ann Hepatol 2004; 3:108-112.
37. Chen L, Jiang YK, Cai YB. Effects of resolving phlegm method on fibrinolytic status in non-alcoholic steatohepatitis patients of phlegm and blood-stasis syndrome. Zhongguo Zhong Xi Yi Jie He Za Zhi 2006; 26:1090-1093.
38. Ji G, Fan JG, Chen JJ, Lu LG, Xing LJ, Zheng PY, et al. Effectiveness of Danning tablet in patients with non-alcoholic fatty liver of damp-heat syndrome type: a multicenter randomized controlled trial. ZhongXi Yi Jie He Xue Bao 2008; 6:128-133. (Pubitemid 351255890)
39. Yang JX, Zou JM, Bai LJ. Clinical observation in the treatment of taurine for non-alcoholic fatty liver disease. Shaanxi Med J Zhi 2007; 36:354-355.
40. Yang QE, Jiang YM, Sun T, Lu YH. Metformin in Combined with Silibinin in the Treatment of Non-Alcoholic Steatohepatitis. Chin J Clin Med 2010; 17:839-840.
41. He JS, Liu GX. Treatment of ursodeoxycholic acid combined polyene phosphatidyl choline for nonalcoholic fatty liver disease. Chin J Mod Drug Appl 2010; 4:105-106.
42. Zhuang XS, Zhang ZJ. Study of ursodeoxycholic acid (UDCA) combined with polyene phosphatidylcholin in the treatment of nonalcoholic steatohepatitis. Chin Practical Med 2009; 4:11 -12.
43. Zhang XW, Zhou M, Hu GQ. Clinical study on nonalcoholic steatohepatitis treated by ursodesoxycholic acid combined with Hugan tablet. Zhongguo Zhong Xi Yi Jie He Za Zhi 2003; 13:8-9.
44. Zhang XL, Wei RP. Study of ursodeoxycholic acid combined silibinin in the treatment of 60 cases of nonalcoholic fatty liver disease. Contemporary Med 2010; 16:48-49.
45. Li T. Study of ursodeoxycholic acid combined essentiale in the treatment of 30 cases non-alcoholic fatty liver disease. Zhejiang Practical Med 2008; 13:169-170.
46. Sun F, Zheng QQ. Cost-effectiveness analyses: ursodeoxycholic acid and essentiale in the treatment of non-alcoholic fatty liver disease. Shaanxi Med J 2010; 39:220-221.
47. Hu M. Study of ursodeoxycholic acid combined metformin in the treatment of nonalcoholic steatohepatitis. Int Med Health Guidance News 2009; 15: 62-65.
48. Hong Q, Zhou SY, Li PD, Chen GW, Chen ZH, Chen QL. Study of ursodeoxycholic acid (UDCA) and essentiale forte N in the treatment of non-alcoholic steatohepatitis. J Guangdong Med Coll 2007; 25:535.
49. Lin ZM, Cai MG, He ZB. Study of ursodeoxycholic acid in the treatment of non-alcoholic fatty liver disease. Strait Pharm J 2009; 21:147-148.
50. Zhu HJ. Clinical observation of ursodeoxycholic acid in the treatment of non-alcoholic steatohepatitis. Med Innovation Chin 2010; 7:85-86.
51. Sun Y Short-term efficacy of ursodeoxycholic acid in the treatment of non-alcoholic fatty liver disease. Mod Health (Med Innovation Res) 2007; 4: 46-47.
52. Wu LJ, Sheng Y, Dang WS, Liu WJ. Ursodeoxycholic acid in treatment of nonalcoholic fatty liver disease. Chin J Postgraduates Med 2006; 29: 35-36, 49.
53. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34:274-285.
54. Dowman JK, Armstrong MJ,Tomlinson JW, Newsome PN. Current therapeutic strategies in non-alcoholic fatty liver disease. Diabetes Obes Metab 2011; 13:692-702.
55. Sanyal AJ, Brunt EM, Kleiner DE, Kowdley KV, Chalasani N, Lavine JE, et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011; 54:344-353.
56. Triantos CK, Koukias NM, Nikolopoulou VN, Burroughs AK. Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis. Aliment Pharmacol Ther 2011; 34:901-910.
57. Chapman RW. Primary sclerosing cholangitis: what is the role of ursodeoxycholic acid in therapy for PSC? Nat Rev Gastroenterol Hepatol 2010; 7:74-75.
58. Eaton JE, Silveira MG, Pardi DS, Sinakos E, Kowdley KV, Luketic VA, et al. High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol 2011; 106:1638-1645.
59. Imam MH, Sinakos E, Gossard AA, Kowdley KV, Luketic VA, Edwyn Harrison M, et al. High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis. Aliment Pharmacol Ther 2011; 34:1185-1192.
60. Sinakos E, Marschall HU, Kowdley KV, Befeler A, Keach J, Lindor K. Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: relation to disease progression. Hepatology 2010; 52:197-203.
61. Orlando R, Azzalini L, Orando S, Lirussi F. Bile acids for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst Rev 2007; 24:CD005160.